EHPC Completed Trials

Title

NIHR ref

RLBUHT

RD&I

LSTM

RD&I

REC

EudraCT 
number:

Primary objective

Where Archived

Funder

EHPC The Effect of Live Attenuated Influenza Vaccine (LAIV) on EHPC

Started 2016

18994

4896

14-058

14/NW/1460

 

EudraCT

2014-004634-26

To define the effect of LAIV on pneumococcal colonisation using the EHPC model in order to assess the potential effects of mass influenza vaccination. We will measure colonisation acquisition, density and duration.

 

MRC and Gates Foundation

EHPC Pilot study of repeated mucosal sampling on experimental human pneumococcal colonization

Started 2015

 

4938

15-027

15/NW/0146

To evaluate if repeated mucosal sampling will obtain sufficient tissue for immunological assessment.

 

 

 

Genocea (phase 2)  pneumococcal otitis media vaccine

Started 2014

17331

4741

14-058

14/NW/0355

To evaluate the effect of Gen-004 on pneumococcal colinazation compared to placebo.

RLBUHT

Pharma: GENOCEA

PCV EHPC

Started 2013

13932

4431

 

12/NW/0873

 

EudraCT

2012-005141-20

To evaluate the effect of PCV on pneumococcal colonization compared to Hep A vaccine (Avaxim).

 

Gates Foundation

Dose ranging and reproducibility

Started 2011

11731

4210

 

11/NW/0592

To establish >40% pneumococcal colonization using 6B and 23F creating a dose range curve and to validate the model by reproducing the findings.

 

BM Gates Foundation